tech providers
Chemical Products for
the performance year
2015.
How do you view
the current market
scenario in India?
What are the
challenges and
opportunities for
bio-suppliers or
technology
providers?
India is the second
largest supplier of
generic drugs by value,
and the largest supplier
by volume to the global
marketplace. Generic
drugs in India include
a broad range of small-
molecule drugs,
over-the-counter
products, AIDS
antiretroviral, oncology
drugs and more. This
includes the increasing
number of
development of large-
molecule drugs, and
54
BioVoiceNews | Dec 2017 - Jan 2018
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
especially generics as
more innovative drug
products come off
patent.
In terms of quality,
there is a tightening of
regulations with major
regulatory agencies,
such as the U.S. FDA
and UK Medicines and
Healthcare products
Regulatory Agency
(MHRA), pushing for
stricter norms for
pharma companies not
only in terms of
manufacturing
practices, but also
where they source their
ingredients or
components. This is
benefiting the industry
in India in general,
particularly as more
and more
multinational
manufacturers like
Avantor look to their
Indian facilities as a
key element in the
global supply chains –
not merely as a facility
that serves the Indian
market. Manufacturers
of both small- and
large-molecule drugs
are being driven to
partner with more
reputable suppliers,
rather than simply
looking solely at price,
which also pushes
other suppliers in the
region to migrate to
higher standards to be
competitive.
India is also working
on some of the
challenges that the
rest of the global
biopharmaceutical
industry faces, like
drug development and
process optimization.
These include
achieving the efficient
production of
therapeutic proteins
and discovering new
approaches for